Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

IQVIA Holdings Inc. focuses on technology solutions and contract research services. The Company offers a broad range of solutions which includes clinical development strategies, therapeutic expertise, predictive and prescriptive analytics, and patient retention services. IQVIA Holdings serves consumer health, biopharma, and medical technology industries globally.
Website: iqvia.com



Growth: Pretty weak revenue growth rate 2.3%, there is slowdown compared to average historical growth rates 8.5%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -7.9%

Profitability: LTM EBITDA margin is positive, +20.9%. On average the margin is improving unsteadily. Gross margin is normal, +27.6%. In the last quarter the company beat the estimated EPS, +1.7%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -3 533.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 32.1% higher than minimum and 19.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.9x by EV / Sales multiple , the company can be 22.3% overvalued

Insiders: For the last 3 months insiders sold company shares on $17.1 mln (-0.036% of cap.)

Key Financials (Download financials)

Ticker: IQV
Share price, USD:  (+1.6%)227.04
year average price 218.31  


year start price 189.82 2023-05-08

min close price 177.16 2023-10-30

max close price 259.10 2024-03-12

current price 227.04 2024-05-07
Common stocks: 189 279 006

Dividend Yield:  0.0%
FCF Yield LTM: -3 533.7%
EV / LTM EBITDA: 17.6x
EV / EBITDA annualized: 17.9x
Last revenue growth (y/y):  2.3%
Last growth of EBITDA (y/y):  6.4%
Historical revenue growth:  8.5%
Historical growth of EBITDA:  11.9%
EV / Sales: 3.7x
Margin (EBITDA LTM / Revenue): 20.9%
Fundamental value created in LTM:
Market Cap ($m): 42 974
Net Debt ($m): 12 296
EV (Enterprise Value): 55 270
Price to Book: 6.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-03Zacks Investment Research

Here's Why IQVIA Holdings (IQV) is a Strong Value Stock

2024-05-02Zacks Investment Research

IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q1

2024-05-02Zacks Investment Research

IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates

2024-04-29Zacks Investment Research

IQVIA (IQV) to Report Q1 Earnings: What's in the Offing?

2024-04-29Zacks Investment Research

Countdown to IQVIA (IQV) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

2024-04-17Zacks Investment Research

Reasons to Retain IQVIA (IQV) Stock in Your Portfolio Now

2024-04-04Zacks Investment Research

Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term

2024-04-02Zacks Investment Research

IQVIA (IQV) Appreciates 24% in a Year: Here's What to Know

2024-03-15Zacks Investment Research

IQVIA (IQV) Up 5.3% Since Last Earnings Report: Can It Continue?

2024-03-13Zacks Investment Research

IQVIA (IQV) Gains From Global IT Framework, Liquidity Low
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IQV IQV IQV IQV IQV IQV IQV
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-02 2024-02-15 2023-11-01 2023-08-01 2023-04-28 2023-02-15 2022-10-27
acceptedDate 2024-05-02 16:32:17 2024-02-15 07:33:24 2023-11-01 16:29:25 2023-08-01 16:22:49 2023-04-28 07:49:59 2023-02-15 16:24:16 2022-10-27 16:24:14
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 3 740M 3 909M 3 736M 3 728M 3 652M 3 739M 3 562M
costOfRevenue 2 708M 2 794M 2 426M 2 443M 2 398M 2 407M 2 321M
grossProfit 1 032M 1 115M 1 310M 1 285M 1 254M 1 332M 1 241M
grossProfitRatio 0.276 0.285 0.351 0.345 0.343 0.356 0.348
researchAndDevelopmentExpenses 0 0 0 0 0 0 0
generalAndAdministrativeExpenses 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 508M 556M 502M 482M 513M 583M 517M
otherExpenses -11M 47M 35M 16M 253M 357M 248M
operatingExpenses 508M 556M 799M 741M 766M 940M 765M
costAndExpenses 3 216M 3 350M 3 225M 3 184M 3 164M 3 347M 3 086M
interestIncome 11M 12M 14M 4M 6M 6M 4M
interestExpense 166M 193M 181M 169M 141M 128M 108M
depreciationAndAmortization 264M 316M 297M 259M 302M 394M 248M
ebitda 788M 875M 857M 823M 773M 773M 709M
ebitdaratio 0.211 0.224 0.229 0.221 0.212 0.207 0.199
operatingIncome 524M 559M 481M 524M 471M 379M 472M
operatingIncomeRatio 0.140 0.143 0.129 0.141 0.129 0.101 0.133
totalOtherIncomeExpensesNet -184M -186M 5M -4M -109M -104M -112M
incomeBeforeTax 340M 373M 349M 375M 362M 275M 360M
incomeBeforeTaxRatio 0.091 0.095 0.093 0.101 0.099 0.074 0.101
incomeTaxExpense 49M -102M 51M 81M 71M 48M 70M
netIncome 288M 469M 303M 297M 289M 227M 283M
netIncomeRatio 0.077 0.120 0.081 0.080 0.079 0.061 0.079
eps 1.580 2.580 1.660 1.610 1.560 1.220 1.520
epsdiluted 1.560 2.540 1.630 1.590 1.530 1.200 1.490
weightedAverageShsOut 182M 182M 183M 184M 186M 186M 187M
weightedAverageShsOutDil 184M 184M 186M 187M 189M 189M 189M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IQV IQV IQV IQV IQV IQV IQV
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-02 2024-02-15 2023-11-01 2023-08-01 2023-04-28 2023-02-15 2022-10-27
acceptedDate 2024-05-02 16:32:17 2024-02-15 07:33:24 2023-11-01 16:29:25 2023-08-01 16:22:49 2023-04-28 07:49:59 2023-02-15 16:24:16 2022-10-27 16:24:14
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1 444M 1 376M 1 224M 1 382M 1 494M 1 216M 1 274M
shortTermInvestments 131M 120M 108M 110M 104M 93M 87M
cashAndShortTermInvestments 1 575M 1 496M 1 332M 1 492M 1 598M 1 309M 1 361M
netReceivables 3 461M 3 413M 3 276M 3 184M 3 105M 2 960M 2 687M
inventory 0 0 177M 179M 165M 151M 0
otherCurrentAssets 615M 687M 423M 474M 460M 561M 704M
totalCurrentAssets 5 651M 5 596M 5 208M 5 329M 5 328M 4 981M 4 752M
propertyPlantEquipmentNet 791M 819M 790M 829M 845M 863M 840M
goodwill 14 516M 14 567M 14 288M 14 178M 14 015M 13 921M 13 177M
intangibleAssets 4 725M 4 839M 4 907M 4 942M 4 757M 4 820M 4 718M
goodwillAndIntangibleAssets 19 241M 19 406M 19 195M 19 120M 18 772M 18 741M 17 895M
longTermInvestments 263M 241M 214M 208M 201M 162M 151M
taxAssets 152M 166M 111M 115M 125M 118M 97M
otherNonCurrentAssets 476M 453M 459M 435M 468M 472M 488M
totalNonCurrentAssets 20 923M 21 085M 20 769M 20 707M 20 411M 20 356M 19 471M
otherAssets 0 0 0 0 0 0 0
totalAssets 26 574M 26 681M 25 977M 26 036M 25 739M 25 337M 24 223M
accountPayables 3 455M 3 564M 3 133M 3 007M 3 143M 3 316M 2 971M
shortTermDebt 717M 825M 1 309M 1 344M 1 343M 152M 151M
taxPayables 155M 116M 172M 208M 187M 161M 124M
deferredRevenue 1 914M 1 799M 1 838M 1 844M 1 827M 1 797M 1 842M
otherCurrentLiabilities 362M 303M 309M 348M 344M 313M 165M
totalCurrentLiabilities 6 448M 6 491M 6 589M 6 543M 6 657M 5 578M 5 253M
longTermDebt 12 819M 12 955M 12 539M 12 675M 12 088M 12 859M 12 502M
deferredRevenueNonCurrent 204M 451M 0 0 0 464M 0
deferredTaxLiabilitiesNonCurrent 164M 202M 365M 367M 421M 464M 560M
otherNonCurrentLiabilities 595M 470M 679M 703M 641M 207M 561M
totalNonCurrentLiabilities 13 782M 14 078M 13 583M 13 745M 13 150M 13 994M 13 623M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 204M 451M 217M 242M 255M 264M 259M
totalLiabilities 20 230M 20 569M 20 172M 20 288M 19 807M 19 572M 18 876M
preferredStock 0 0 0 0 0 0 0
commonStock 3M 3M 10 994M 10 952M 10 909M 10 898M 10 853M
retainedEarnings 4 980M 4 692M 4 223M 3 920M 3 623M 3 334M 3 107M
accumulatedOtherComprehensiveIncomeLoss -911M -867M -903M -760M -731M -727M -898M
othertotalStockholdersEquity 2 272M 2 284M -8 509M -8 364M -7 869M -7 740M 0
totalStockholdersEquity 6 344M 6 112M 5 805M 5 748M 5 932M 5 765M 5 347M
totalEquity 6 344M 6 112M 5 805M 5 748M 5 932M 5 765M 5 347M
totalLiabilitiesAndStockholdersEquity 26 574M 26 681M 25 977M 26 036M 25 739M 25 337M 24 223M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 26 574M 26 681M 25 977M 26 036M 25 739M 25 337M 24 223M
totalInvestments 394M 361M 99M 101M 206M 161M 238M
totalDebt 13 740M 14 231M 13 848M 14 019M 13 431M 13 011M 12 653M
netDebt 12 296M 12 855M 12 624M 12 637M 11 937M 11 795M 11 379M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IQV IQV IQV IQV IQV IQV IQV
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-02 2024-02-15 2023-11-01 2023-08-01 2023-04-28 2023-02-15 2022-10-27
acceptedDate 2024-05-02 16:32:17 2024-02-15 07:33:24 2023-11-01 16:29:25 2023-08-01 16:22:49 2023-04-28 07:49:59 2023-02-15 16:24:16 2022-10-27 16:24:14
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 288M 469M 303M 297M 289M 227M 283M
depreciationAndAmortization 264M 316M 297M 259M 253M 357M 248M
deferredIncomeTax -66M -152M -47M -43M -27M -63M -24M
stockBasedCompensation 56M 45M 47M 50M 75M 58M 61M
changeInWorkingCapital -16M 73M -22M -156M -175M -5M 278M
accountsReceivables 65M -254M -107M -27M -107M -278M 0
inventory 0 121M 0 0 0 0 0
accountsPayables 0 267M 0 0 0 427M 0
otherWorkingCapital -16M -61M 85M -129M -68M -154M 366M
otherNonCashItems 580M -4M 5M -5M 2M -14M 17M
netCashProvidedByOperatingActivities 522M 747M 583M 402M 417M 560M 863M
investmentsInPropertyPlantAndEquipment -145M -179M -146M -160M -164M -171M -165M
acquisitionsNet -142M -7M -428M -432M -25M -309M -552M
purchasesOfInvestments -27M -27M -3M 0 -40M -1 000 000 -1 000 000
salesMaturitiesOfInvestments 0 -38M 3M 0 0 0 0
otherInvestingActivites -27M 39M 1 000 000 -4M 7M 4M 1 000 000
netCashUsedForInvestingActivites -314M -212M -573M -596M -222M -477M -717M
debtRepayment -43M -186M -441M -1 722M -139M -973M -389M
commonStockIssued 0 0 0 0 0 0 0
commonStockRepurchased 0 -171M -144M -490M -129M -65M -210M
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -63M -63M 441M 2 307M 355M 845M 348M
netCashUsedProvidedByFinancingActivities -106M -420M -144M 95M 87M -193M -251M
effectOfForexChangesOnCash -34M 37M -24M -13M -4M 52M -49M
netChangeInCash 68M 152M -158M -112M 278M -58M -154M
cashAtEndOfPeriod 1 444M 1 376M 1 224M 1 382M 1 494M 1 216M 1 274M
cashAtBeginningOfPeriod 1 376M 1 224M 1 382M 1 494M 1 216M 1 274M 1 428M
operatingCashFlow 522M 747M 583M 402M 417M 560M 863M
capitalExpenditure -145M -179M -146M -160M -164M -171M -165M
freeCashFlow 377M 568M 437M 242M 253M 389M 698M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-10 ET (fiscal 2022 q4)
2022 q3
2022-10-26 ET (fiscal 2022 q3)
2022 q2
2022-07-21 ET (fiscal 2022 q2)
2022 q1
2022-04-27 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-02 11:00 ET
IQVIA Reports First-Quarter 2024 Results
2024-04-23 13:00 ET
IQVIA Celebrates Wendy Stewart and Susan Barnes, Winners of Healthcare Businesswoman's Association Luminary and Rising Star Awards
2024-04-15 20:15 ET
IQVIA to Announce First-Quarter 2024 Results on May 2, 2024
2024-04-08 20:01 ET
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud
2024-02-26 13:00 ET
IQVIA Publishes its 2023 Environmental, Social and Governance Report
2024-02-23 14:00 ET
Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report
2024-02-21 21:15 ET
IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024
2024-02-14 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
2024-02-06 14:00 ET
IQVIA Named to Fortune® World's Most Admired Companies™ List, Ranked #1 in Its Sector for the Third Consecutive Year
2024-01-24 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024
2024-01-17 11:00 ET
Global Medicine Spending to Reach $2.3 Trillion by 2028 as More Patients Get Access to Better Therapies, Says IQVIA Institute Report
2023-11-29 13:30 ET
IQVIA Digital Enablement Named PM360 Trailblazer 2023 Supplier/Vendor of the Year
2023-11-21 21:15 ET
IQVIA CFO Ron Bruehlman to Speak at Evercore HealthCONx Conference on November 29, 2023
2023-11-17 14:23 ET
IQVIA Announces Upsizing of its Allocation of New Term B Loans
2023-11-15 14:11 ET
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes
2023-11-14 14:07 ET
IQVIA Announces Offering of Senior Secured Notes
2023-11-06 13:00 ET
IQVIA’s Christina Mack Named 2023 PharmaVoice 100 Honoree
2023-11-01 11:00 ET
IQVIA Reports Third-Quarter 2023 Results
2023-10-23 12:00 ET
IQVIA to Provide Sanofi Its Orchestrated Customer Engagement (OCE) Platform in Africa & Middle East
2023-10-11 11:30 ET
IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission
2023-10-09 20:15 ET
IQVIA to Announce Third-Quarter 2023 Results on November 1, 2023
2023-10-05 12:00 ET
Patient Organizations Gave $22 Billion in Grants for Research, Patient Services, and Access to Care Over the Last 5 Years, Says IQVIA Institute for Human Data Science
2023-10-03 12:00 ET
IQVIA Builds on its Strategic Collaboration with argenx to Provide Safety Systems and Services
2023-09-26 00:01 ET
IQVIA Appoints Richard Staub III President of Research & Development Solutions
2023-09-12 12:30 ET
IQVIA Named a Leader in Pharmacovigilance Solutions in IDC MarketScape Report
2023-09-05 12:30 ET
IQVIA CFO Ron Bruehlman to Speak at Baird Global Healthcare Conference on September 13, 2023
2023-09-01 12:30 ET
IQVIA CEO Ari Bousbib to Speak at Morgan Stanley Annual Global Healthcare Conference on September 12, 2023
2023-08-01 11:00 ET
IQVIA Reports Second-Quarter 2023 Results
2023-07-06 20:15 ET
IQVIA to Announce Second-Quarter 2023 Results on August 1, 2023
2023-07-05 15:00 ET
IQVIA and the NBA Selected for Abbott’s UNIVANTS of Healthcare Excellence Award
2023-06-29 12:30 ET
IQVIA selected ‘Leader’ in Everest Group Life Sciences Sales and Marketing Operations PEAK Matrix® Assessment 2023
2023-06-27 13:30 ET
IQVIA Wins Prestigious “Best AI-based Solution for Healthcare” Award in 2023 Artificial Intelligence Breakthrough Awards
2023-06-26 12:30 ET
IQVIA Launches RIM Smart Labeling to Deliver Intelligence-Driven Approach for Global Label Management
2023-05-25 06:00 ET
IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening
2023-05-24 12:00 ET
Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science
2023-05-18 20:38 ET
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes and Senior Notes
2023-05-18 12:25 ET
IQVIA Announces Offering of Senior Secured Notes and Senior Notes
2023-05-11 15:00 ET
IQVIA Celebrates Sheetal Telang, Winner of Healthcare Businesswoman's Association Rising Star Award
2023-05-02 12:00 ET
Use of Medicines in the U.S. Continued to Grow in 2022 while Patient Out-of-Pocket Costs Remain Low, Says IQVIA Institute
2023-04-27 11:00 ET
IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance
2023-04-20 15:00 ET
IQVIA Named a Leader in Everest Group Life Sciences Customer Experience Platforms PEAK Matrix® Assessment 2023
2023-04-06 20:15 ET
IQVIA to Announce First-Quarter 2023 Results on April 27, 2023
2023-03-14 12:00 ET
Global Clinical Trial Activity Remained Resilient in 2022 Despite The Continued Pandemic, Says IQVIA Institute
2023-03-01 21:15 ET
IQVIA CFO Ron Bruehlman to Speak at Barclays Global Healthcare Conference on March 15, 2023
2023-02-23 16:00 ET
IQVIA Publishes its 2022 Environmental, Social and Governance Report
2023-02-10 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance
2023-02-09 17:00 ET
IQVIA Named to FORTUNE’s 2023 List of “World’s Most Admired Companies,” Ranked #1 in Its Category for the Second Consecutive Year
2023-01-31 13:30 ET
IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial & Clinical Solutions in China
2023-01-25 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2022 Results on February 10, 2023
2023-01-18 13:00 ET
Global Market for Medicines to Rise to $1.9 Trillion by 2027, says Report from IQVIA Institute
2023-01-03 16:05 ET
Lasso announces a significant step forward in healthcare marketing measurement
2022-12-28 13:30 ET
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
2022-11-10 16:00 ET
IQVIA and Clalit Health Services partner to advance research by launching the first Prime Site in Israel
2022-10-26 11:00 ET
IQVIA Reports Third-Quarter 2022 Results
2022-10-24 20:15 ET
IQVIA CFO Ron Bruehlman to Speak at Credit Suisse Annual Healthcare Conference on November 8, 2022
2022-10-06 12:15 ET
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
2022-10-03 20:15 ET
IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022
2022-09-28 14:00 ET
IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation
2022-09-07 12:15 ET
New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials
2022-09-02 12:15 ET
IQVIA CEO Ari Bousbib to Speak at Baird Global Healthcare Conference on September 14, 2022
2022-09-01 20:15 ET
IQVIA CFO Ron Bruehlman to Speak at Morgan Stanley Annual Global Healthcare Conference on September 13, 2022
2022-08-15 11:30 ET
IQVIA Wins Snowflake’s “Marketplace Healthcare and Life Sciences Partner of the Year” Award
2022-07-21 11:00 ET
IQVIA Reports Second-Quarter 2022 Results
2022-07-07 20:15 ET
IQVIA to Announce Second-Quarter 2022 Results on July 21, 2022
2022-07-06 11:30 ET
IQVIA Recognized as a Leader in Life Science Sales and Marketing IT Outsourcing Services
2022-06-07 12:00 ET
IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions
2022-06-01 12:00 ET
Global Oncology R&D Surges While Cancer Care Disruptions Ease, Says IQVIA Institute for Human Data Science
2022-05-25 20:43 ET
IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022
2022-04-27 11:00 ET
IQVIA Reports First-Quarter 2022 Results
2022-04-21 12:00 ET
Spending on U.S. Medicines Rose 12% in 2021 Due to COVID-19 Vaccines and Therapies, Says IQVIA Institute for Human Data Science
2022-04-12 20:15 ET
IQVIA to Announce First-Quarter 2022 Results on April 27, 2022
2022-03-30 22:00 ET
IQVIA Selected to Support EMA’s DARWIN EU® Coordination Centre Initiative
2022-03-15 22:05 ET
IQVIA Launches OCE+ To Deliver Enhanced AI-Driven Customer Engagement
2022-03-14 13:00 ET
IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)
2022-03-03 21:15 ET
IQVIA CFO to Speak at Barclays Global Healthcare Conference on March 16, 2022
2022-03-01 13:00 ET
IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod alfa fcab) by argenx SE
2022-02-24 13:00 ET
IQVIA Named Top CRO in 2021 WCG CenterWatch Independent Survey
2022-02-22 13:00 ET
IQVIA Releases 2021 Environmental, Social, and Governance (ESG) Report
2022-02-15 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2021 Results; Raises Full-Year 2022 Profit Guidance
2022-02-10 21:15 ET
IQVIA CFO Ron Bruehlman to Speak at Citi’s 2022 Virtual Healthcare Conference on February 24, 2022
2022-02-10 13:00 ET
Pharma R&D Pipeline and New Product Launches Reach Record Levels in 2021 According to New IQVIA Institute for Human Data Science Report
2022-02-02 13:40 ET
IQVIA Named to FORTUNE’s 2022 List of “World’s Most Admired Companies,” Ranked #1 in Health Care: Pharmacy and Other Services
2022-02-01 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2021 Results on February 15, 2022
2022-01-26 22:01 ET
Sheila A. Stamps Joins IQVIA Board of Directors
2022-01-24 22:00 ET
Leslie Wims Morris Joins IQVIA Board of Directors
2021-12-09 13:00 ET
Global Medicine Spending to Reach $1.8 Trillion in 2026, Including Spending on COVID-19 Vaccines, According to Study by the IQVIA Institute for Human Data Science
2021-12-06 12:00 ET
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
2021-12-02 13:00 ET
IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Services Unit
2021-12-01 13:00 ET
IQVIA Recognized as a Leader in BPO Solutions for Pharmaceutical Sales and Marketing
2021-11-18 13:00 ET
IQVIA Launches New Grants/Funding Management Module for Its Orchestrated Customer Engagement Platform
2021-10-21 11:00 ET
IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance
2021-10-12 12:00 ET
IQVIA to Announce Third-Quarter 2021 Results on October 21, 2021
2021-10-07 15:00 ET
IQVIA to Host Financial Analyst and Investor Conference on November 16, 2021
2021-10-06 12:00 ET
IQVIA Announces Opening of New Q² Solutions Innovation Laboratories in North Carolina, Creating New Jobs and Expanded Capabilities
2021-09-30 12:00 ET
Polpharma Selects IQVIA's Orchestrated Customer Engagement Platform to Improve Salesforce Productivity
2021-09-13 20:15 ET
IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment
2021-09-08 12:00 ET
IQVIA Collaborates with HealthCore to Advance Clinical Research Using Real-World Data
2021-09-02 20:15 ET
IQVIA CFO, Ron Bruehlman, to Speak at the Baird 2021 Global Healthcare Conference on September 14, 2021
2021-09-01 12:00 ET
IQVIA Launches New A.I.-Powered MI Contact Center For Life Sciences
2021-07-27 11:00 ET
IQVIA Reports Second-Quarter 2021 Results and Raises Full-Year 2021 Guidance
2021-07-22 12:00 ET
Consumer Health Apps and Digital Health Tools Proliferate, Improving Quality and Health Outcomes for Patients, Says New Report from IQVIA Institute
2021-07-13 20:15 ET
IQVIA to Announce Second-Quarter 2021 Results on July 27, 2021
2021-06-24 20:15 ET
IQVIA Launches the Clinical Data Analytics Suite (CDAS) to Enable Smarter, Faster Clinical Trials
2021-06-14 12:00 ET
Q² Solutions Announces Significant Expansion of Laboratory Operations in Scotland, UK
2021-06-08 12:00 ET
Q² Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials
2021-06-03 20:30 ET
Global Oncology Innovation Continues Despite Pandemic; Global R&D Pipeline Reached 3,500 New Drugs in 2020, up 75% from 2015, Says New Report from the IQVIA Institute for Human Data Science
2021-05-20 20:15 ET
IQVIA CFO, Ron Bruehlman, to Speak at the William Blair Growth Stock Conference on June 2, 2021
2021-05-19 12:00 ET
Pharma R&D Activity Surges Even Without COVID-19, Says Report from the IQVIA Institute for Human Data Science
2021-05-12 12:00 ET
ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions
2021-05-11 13:03 ET
Despite Disinformation Attempt, Antitrust Case Against IQVIA Moves Forward and Report of FTC Investigation of IQVIA Comes to Light
2021-05-10 12:00 ET
U.S. District Court Issues Favorable Decision for IQVIA Against Veeva
2021-05-03 12:00 ET
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug
2021-04-29 12:00 ET
Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study
2021-04-28 12:00 ET
IQVIA Announces Connected Intelligence™
2021-04-22 11:00 ET
IQVIA Reports First-Quarter Results; Raises Full-Year 2021 Guidance
2021-04-06 17:00 ET
IQVIA to Announce First-Quarter 2021 Results on April 22, 2021
2021-04-06 11:30 ET
Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
2021-04-01 11:03 ET
Quest Diagnostics Sells Ownership Interest in Q² Solutions to IQVIA
2021-04-01 11:00 ET
IQVIA Acquires Remaining Interest in Q² Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance
2021-03-09 13:00 ET
IQVIA Virtual Trial Solutions Used in More than 60 Trials
2021-03-08 13:00 ET
IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials
2021-03-02 21:15 ET
IQVIA to Participate in the Barclays Global Healthcare Conference on March 09, 2021
2021-02-17 21:27 ET
IQVIA Announces Pricing of Offering of Senior Notes
2021-02-16 08:26 ET
IQVIA Announces Offering of Senior Notes
2021-02-11 13:00 ET
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Selected by 140 Life Sciences Companies in Nearly 90 Countries
2021-02-10 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2020 Results Raises Full-Year 2021 Guidance
2021-02-04 13:00 ET
IQVIA Recognized as Leading eCOA/ePRO Provider in Latest 2020 ISR eCOA/ePRO Market Report
2021-02-01 13:00 ET
IQVIA Named to FORTUNE’s 2021 List of “World’s Most Admired Companies”
2021-01-26 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2020 Results on February 10, 2021
2021-01-05 13:00 ET
Laboratoires Théa Selects IQVIA OCE and OneKey to Accelerate Its Global Digital Transformation
2020-12-21 12:30 ET
Q² Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution
2020-12-17 13:00 ET
Prescription Opioid Use in the U.S. has Declined by 60% from 2011 Peak, According to New Report from the IQVIA™ Institute for Human Data Science
2020-12-16 13:00 ET
IQVIA and Servier Collaborate to Reinvent Clinical Development
2020-12-07 13:00 ET
IQVIA Supports Collaborative Forum of Top Pharma Leaders to Advance the Use and Acceptance of Real World Evidence
2020-11-02 13:00 ET
IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities
2020-10-20 11:00 ET
IQVIA Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and Provides 2021 Outlook
2020-10-12 12:00 ET
IQVIA Joins FDA to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project
2020-10-07 20:15 ET
IQVIA to Announce Third-Quarter Results on October 20, 2020
2020-10-06 12:00 ET
IQVIA Institute for Human Data Science Study: Biosimilars Reach Inflection Point – On Track to Reduce Drug Costs by $100 Bn Over Next Five Years
2020-09-14 12:10 ET
IQVIA’s eCOA Solution Receives 2020 Fierce Innovation Award
2020-08-31 12:58 ET
IQVIA’s RIM Smart Honored as Gold Stevie® Award Winner in 2020 American Business Awards®
2020-08-05 12:00 ET
IQVIA’s Nancy Dreyer and Deepa Desai Honored with 2020 PharmaVOICE Awards
2020-08-04 12:00 ET
Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science
2020-07-29 12:00 ET
IQVIA Launches OCE Optimizer to Help Intelligently Plan HCP Engagements and Maximize Commercial Effectiveness
2020-07-23 12:00 ET
IQVIA Human Data Science Research Collaborative Initiative Waives Data Access Fees for Academic Researchers
2020-07-22 11:00 ET
IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance
2020-07-21 22:00 ET
IQVIA Appoints Ron Bruehlman Executive Vice President and interim Chief Financial Officer
2020-07-21 22:00 ET
Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
2020-07-20 12:01 ET
IQVIA and JDRF Collaborate to Improve Understanding of Type 1 Diabetes Using Real World Data
2020-07-14 12:00 ET
IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine
2020-07-08 20:15 ET
IQVIA to Announce Second-Quarter Results on July 22, 2020
2020-07-02 12:00 ET
IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada
2020-06-10 21:58 ET
IQVIA Announces Pricing of Offering of Senior Notes
2020-04-28 11:00 ET
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance
2020-02-13 21:41 ET
IQVIA Announces Repurchase of Common Stock
2020-02-12 12:00 ET
IQVIA Reports Fourth-Quarter and Full-Year 2019 Results Issues First-Quarter and Full-Year 2020 Guidance
2020-01-29 21:15 ET
IQVIA to Announce Fourth-Quarter and Full-Year 2019 Results and Issue 2020 Guidance on February 12, 2020
2020-01-21 13:00 ET
IQVIA Named to FORTUNE’s 2020 List of “World’s Most Admired Companies”

SEC forms

Show financial reports only

SEC form 10
2024-05-02 16:32 ET
IQVIA published news for 2024 q1
SEC form 8
2024-05-02 08:41 ET
IQVIA reported for 2024 q1
SEC form 8
2024-05-02 08:41 ET
IQVIA published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
IQVIA published news for 2024 q1
SEC form 10
2024-02-15 00:00 ET
IQVIA reported for 2023 q4
SEC form 8
2024-02-14 00:00 ET
IQVIA published news for 2023 q4
SEC form 8
2024-02-14 00:00 ET
IQVIA published news for 2023 q4
SEC form 10
2023-11-01 16:29 ET
IQVIA published news for 2023 q3
SEC form 8
2023-11-01 07:05 ET
IQVIA reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
IQVIA published news for 2023 q3
SEC form 10
2023-08-01 16:22 ET
IQVIA published news for 2023 q2
SEC form 6
2023-08-01 07:05 ET
IQVIA reported for 2023 q2
SEC form 8
2023-08-01 00:00 ET
IQVIA published news for 2023 q2
SEC form 10
2023-08-01 00:00 ET
IQVIA published news for 2023 q2
SEC form 10
2023-04-28 00:00 ET
IQVIA published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
IQVIA published news for 2023 q1
SEC form 6
2023-04-17 19:45 ET
IQVIA published news for 2023 q1
SEC form 10
2023-02-15 16:24 ET
IQVIA reported for 2022 q4
SEC form 10
2023-02-15 00:00 ET
IQVIA reported for 2022 q4
SEC form 6
2023-02-13 16:31 ET
IQVIA published news for 2022 q4
SEC form 6
2023-02-10 07:02 ET
IQVIA published news for 2022 q4
SEC form 8
2023-02-10 00:00 ET
IQVIA reported for 2022 q4
SEC form 10
2022-10-27 16:24 ET
IQVIA reported for 2022 q3
SEC form 10
2022-10-27 00:00 ET
IQVIA reported for 2022 q3
SEC form 6
2022-10-26 07:05 ET
IQVIA published news for 2022 q3
SEC form 8
2022-10-26 00:00 ET
IQVIA reported for 2022 q3
SEC form 6
2022-10-03 07:00 ET
IQVIA published news for 2022 q3
SEC form 6
2022-08-05 17:18 ET
IQVIA published news for 2022 q2
SEC form 6
2022-07-29 16:15 ET
IQVIA published news for 2022 q2
SEC form 10
2022-07-22 16:22 ET
IQVIA reported for 2022 q2
SEC form 10
2022-07-22 00:00 ET
IQVIA reported for 2022 q2
SEC form 6
2022-07-21 07:05 ET
IQVIA published news for 2022 q2
SEC form 8
2022-07-21 00:00 ET
IQVIA reported for 2022 q2
SEC form 6
2022-06-16 17:26 ET
IQVIA published news for 2022 q1
SEC form 10
2022-04-28 16:18 ET
IQVIA reported for 2022 q1
SEC form 10
2022-04-28 00:00 ET
IQVIA reported for 2022 q1
SEC form 6
2022-04-27 07:05 ET
IQVIA published news for 2022 q1
SEC form 8
2022-04-27 00:00 ET
IQVIA reported for 2022 q1
SEC form 6
2022-04-14 16:48 ET
IQVIA published news for 2022 q1
SEC form 6
2022-03-17 17:05 ET
IQVIA published news for 2021 q4
SEC form 6
2022-03-14 17:03 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-28 16:48 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-18 16:44 ET
IQVIA published news for 2021 q4
SEC form 10
2022-02-16 16:22 ET
IQVIA published news for 2021 q4
SEC form 10
2022-02-16 00:00 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-15 07:05 ET
IQVIA published news for 2021 q4
SEC form 8
2022-02-15 00:00 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-02 17:08 ET
IQVIA published news for 2021 q4
SEC form 6
2022-02-02 17:03 ET
IQVIA published news for 2021 q4
SEC form 6
2022-01-26 17:46 ET
IQVIA published news for 2021 q4
SEC form 10
2021-10-22 07:55 ET
IQVIA published news for 2021 q3
SEC form 10
2021-10-22 00:00 ET
IQVIA published news for 2021 q3
SEC form 6
2021-10-21 07:05 ET
IQVIA published news for 2021 q3
SEC form 8
2021-10-21 00:00 ET
IQVIA published news for 2021 q3
SEC form 6
2021-08-25 16:54 ET
IQVIA published news for 2021 q2
SEC form 10
2021-07-28 16:14 ET
IQVIA published news for 2021 q2
SEC form 10
2021-07-28 00:00 ET
IQVIA published news for 2021 q2
SEC form 6
2021-07-27 07:05 ET
IQVIA published news for 2021 q2
SEC form 8
2021-07-27 00:00 ET
IQVIA reported for 2021 q2
SEC form 10
2021-04-23 16:12 ET
IQVIA published news for 2021 q1
SEC form 10
2021-04-23 00:00 ET
IQVIA published news for 2021 q1
SEC form 6
2021-04-22 07:05 ET
IQVIA published news for 2021 q1
SEC form 8
2021-04-22 00:00 ET
IQVIA published news for 2021 q1
SEC form 6
2021-04-16 17:00 ET
IQVIA published news for 2021 q1
SEC form 6
2021-04-01 07:05 ET
IQVIA published news for 2021 q1
SEC form 6
2021-03-03 16:39 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-26 17:19 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-17 16:44 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-16 17:06 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-16 06:20 ET
IQVIA published news for 2020 q4
SEC form 10
2021-02-12 16:16 ET
IQVIA published news for 2020 q4
SEC form 6
2021-02-10 07:05 ET
IQVIA published news for 2020 q4
SEC form 10
2020-10-22 16:05 ET
IQVIA published news for 2020 q3
SEC form 6
2020-10-20 07:05 ET
IQVIA published news for 2020 q3